This market report summarizes the results of HTStec's industry-wide global web-based benchmarking survey on phenotypic drug discovery (PDD) carried out in March 2013. The survey was initiated by HTStec as part of its tracking of this emerging life science marketplace.
The survey looked at the following aspects of PDD, as practiced today (2013) and in a few cases as predicted for the future (2015):
- Current level of deployment (actual use); what features most highly the understanding of PDD
- Importance of features in the definition/understanding of a phenotypic screening assay
- Different assay types that fit within the definition/understanding of a phenotypic screening assay
- Key diseases/therapeutic area(s) deploying phenotypic screening assays
- Main motivators for wanting to adopt PDD
- Key challenges of doing PDD
- Obstacles which would most limit the adoption of phenotypic screening assays today
- Number of FTE devoted in house to PPD
- The number of primary phenotypic screens and data points per screen
- The average cost per well of phenotypic screening assays
- (Much more included in the full report)
Key Points Discussed in the Report:
(The Contents on this Website is a Condensed Version of the Original Report. To View the Complete Version, Please Request a Sample.)
- Target deconvolution was rated the main obstacle limiting adoption of phenotypic screening assays.
- The median cost of a phenotypic screening assay undertaken in 2013 was $0.5-$0.75 per well.
- Human primary cells were ranked the cell type most relevant for phenotypic screening studies.
- The median success rate for phenotypic primary screening in 2013 was 40%.